199 related articles for article (PubMed ID: 15613472)
1. Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.
Müller P; Ceskova P; Vojtesek B
J Biol Chem; 2005 Feb; 280(8):6682-91. PubMed ID: 15613472
[TBL] [Abstract][Full Text] [Related]
2. Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.
Ikeda J; Tada M; Ishii N; Saya H; Tsuchiya K; Okaichi K; Mishima K; Sawamura Y; Fulci G; Liu TJ; Van Meir EG
Int J Cancer; 2001 Oct; 94(1):35-43. PubMed ID: 11668476
[TBL] [Abstract][Full Text] [Related]
3. Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD; Wang Y; Tretyachenko-Ladokhina V; Tan M; Senear DF; Luecke H
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2146-56. PubMed ID: 24100332
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological reactivation of p53 in the era of precision anticancer medicine.
Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
Nat Rev Clin Oncol; 2024 Feb; 21(2):106-120. PubMed ID: 38102383
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.
Hernández Borrero LJ; El-Deiry WS
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188556. PubMed ID: 33932560
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.
Lü Y; Cho T; Mukherjee S; Suarez CF; Gonzalez-Foutel NS; Malik A; Martinez S; Dervovic D; Oh RH; Langille E; Al-Zahrani KN; Hoeg L; Lin ZY; Tsai R; Mbamalu G; Rotter V; Ashton-Prolla P; Moffat J; Chemes LB; Gingras AC; Oren M; Durocher D; Schramek D
Mol Syst Biol; 2024 Jun; 20(6):719-740. PubMed ID: 38580884
[TBL] [Abstract][Full Text] [Related]
7. A glucosinolate mutant of Arabidopsis is thermosensitive and defective in cytosolic Hsp90 expression after heat stress.
Ludwig-Müller J; Krishna P; Forreiter C
Plant Physiol; 2000 Jul; 123(3):949-58. PubMed ID: 10889243
[TBL] [Abstract][Full Text] [Related]
8. Colletofragarone A2 Inhibits Cancer Cell Growth
Sadahiro Y; Hitora Y; Kimura I; Hitora-Imamura N; Onodera R; Motoyama K; Tsukamoto S
Chem Res Toxicol; 2022 Sep; 35(9):1598-1603. PubMed ID: 36027604
[TBL] [Abstract][Full Text] [Related]
9. Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile.
Brown K; Jenkins LMM; Crooks DR; Surman DR; Mazur SJ; Xu Y; Arimilli BS; Yang Y; Lane AN; Fan TW; Schrump DS; Linehan WM; Ripley RT; Appella E
Front Oncol; 2022; 12():1094210. PubMed ID: 36713582
[No Abstract] [Full Text] [Related]
10. Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer.
Falcicchio M; Ward JA; Macip S; Doveston RG
Cell Death Discov; 2020 Nov; 6(1):126. PubMed ID: 33298896
[TBL] [Abstract][Full Text] [Related]
11. Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.
Jagosova J; Pitrova L; Slovackova J; Ravcukova B; Smarda J; Smardova J
Int J Oncol; 2012 Sep; 41(3):1157-63. PubMed ID: 22710932
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer.
Ye G; Zhang X; Li M; Lin Z; Xu Y; Dong H; Zhou J; Zhang J; Wang S; Zhu Y; Yu X; Qian X
BMC Cancer; 2023 May; 23(1):412. PubMed ID: 37158852
[TBL] [Abstract][Full Text] [Related]
13. High FN1 expression is associated with poor survival in esophageal squamous cell carcinoma.
Ma J; Chen S; Su M; Wang W
Medicine (Baltimore); 2023 Apr; 102(14):e33388. PubMed ID: 37026938
[TBL] [Abstract][Full Text] [Related]
14. RNA-Seq Analysis of Extradomain A and Extradomain B Fibronectin as Extracellular Matrix Markers for Cancer.
Hall RC; Vaidya AM; Schiemann WP; Pan Q; Lu ZR
Cells; 2023 Feb; 12(5):. PubMed ID: 36899821
[TBL] [Abstract][Full Text] [Related]
15. Characterization of fibronectin properties by integrated micro-fluidic experiments and fluid-structure interaction simulations.
Ke R; Kucukal E; Gurkan UA; Li B
J Biomech; 2023 Mar; 150():111505. PubMed ID: 36867952
[TBL] [Abstract][Full Text] [Related]
16. A high-impact FN1 variant correlates with fibronectin-mediated glomerulopathy via decreased binding to collagen type IV.
Qiu J; Chi H; Gan C; Zhou X; Chen D; Yang Q; Chen Y; Wang M; Yang H; Jiang W; Li Q
Pathology; 2023 Jun; 55(4):498-507. PubMed ID: 36774238
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Strategies to Activate p53.
Aguilar A; Wang S
Pharmaceuticals (Basel); 2022 Dec; 16(1):. PubMed ID: 36678521
[TBL] [Abstract][Full Text] [Related]
18. Analysis of COL7A1 pathogenic variants in a large cohort of dystrophic epidermolysis bullosa patients from Argentina reveals a new genotype-phenotype correlation.
Natale MI; Manzur GB; Lusso SB; Cella E; Giovo ME; Andrada R; Goitia J; Fernández MF; Della Giovanna PS; Guillamondegui MJ; Domínguez M; Gutiérrez O; Izquierdo A; Hernández Herrera H; Velázquez Perdomo LG; Mistchenko AS; Valinotto LE
Am J Med Genet A; 2022 Nov; 188(11):3153-3161. PubMed ID: 35979658
[TBL] [Abstract][Full Text] [Related]
19. COL7A1 G2287R mutation with two clinical phenotypes in the same family: Bullous dermolysis of the newborn and dystrophic epidermolysis bullosa pruriginosa.
Chao YC; Hong JB; Liu C; Lee MS; Lin RY
J Dermatol; 2022 Sep; 49(9):e313-e314. PubMed ID: 35560343
[No Abstract] [Full Text] [Related]
20. Two cases of the intermediate phenotype of recessive dystrophic epidermolysis bullosa harboring the novel COL7A1 mutation c.3570G>A.
Akasaka E; Nakano H; Sawamura D
J Dermatol Sci; 2022 Jun; 106(3):193-195. PubMed ID: 35527172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
